论文部分内容阅读
背景与目的:Cetuximab联合放疗或化疗治疗头颈恶性肿瘤的报道不多。本研究总结Cetuximab与放疗或化疗联合治疗头颈恶性肿瘤的近期疗效。方法:选取2005年10月1日至2008年9月30日在中山大学肿瘤防治中心,采用Cetuximab与放疗联合治疗(联合放疗组)的6例,及采用Cetuximab与化疗联合治疗(联合化疗组)的5例头颈恶性肿瘤患者,回顾性分析其近期治疗效果和安全性。结果:共计完成82个Cetuximab治疗周期(中位周期数是7),没有因为Cetuximab毒性而停止治疗的患者,没有治疗相关死亡。联合放疗组中4例达到了完全缓解(complete remission,CR),2例部分缓解(partial remission,PR)。4例CR者都有痤疮样皮疹,3例为Ⅲ度以上。而2例PR者有1例Ⅰ度皮疹。5例Cetuximab同期放化疗者都有放射野皮肤反应,4例为Ⅲ度以上。放疗组的血液学毒性除1例为Ⅳ度外,其他5例都比较轻。联合化疗组5例中PR、SD(疾病稳定,stable disease)和PD(疾病进展,progressed disease)分别有2例、2例和1例。联合化疗组的皮疹发生率不高,Ⅲ度以上骨髓抑制有3例。结论:Cetuximab与放疗联合效果较好,但放射野皮肤反应比较大;Cetuximab和化疗联合也是晚期头颈肿瘤的有效选择之一。Cetuximab在中国人头颈肿瘤中的有效性和安全性需要积累更多的资料。
Background and Objective: Cetuximab combined with radiotherapy or chemotherapy in the treatment of head and neck cancer is poorly reported. This study summarizes the recent efficacy of Cetuximab in combination with radiotherapy or chemotherapy for the treatment of head and neck malignancies. Methods: Six cases of Cetuximab combined with radiotherapy (combination radiotherapy group) and Cetuximab combined with chemotherapy (combination chemotherapy group) were selected from Cancer Center of Sun Yat-sen University from October 1, 2005 to September 30, Of 5 cases of head and neck cancer patients, retrospective analysis of its recent treatment and safety. RESULTS: A total of 82 cycles of Cetuximab (median 7 cycles) were completed, and there were no treatment-related deaths in those patients who did not discontinue treatment due to Cetuximab toxicity. In the combination radiotherapy group, 4 patients achieved complete remission (CR) and 2 patients achieved partial remission (PR). All 4 CR patients had an acne-like rash, with 3 cases of Ⅲ degree or more. In the two PRs, there was 1 degree rash. 5 cases of Cetuximab concurrent radiochemotherapy have radiation field skin reaction, 4 cases of Ⅲ degree or more. Radiotherapy group hematological toxicity in addition to 1 case of Ⅳ degrees, the other 5 cases are relatively light. In the combination chemotherapy group, there were 2 cases, 2 cases and 1 case of PR, SD (stable disease) and PD (progressed disease) respectively in 5 cases. The incidence of rash in the combined chemotherapy group was not high, and there were 3 cases of bone marrow suppression above the third degree. Conclusions: Cetuximab combined with radiotherapy is better, but radiotherapy skin reaction is relatively large. Cetuximab combined with chemotherapy is also an effective choice for advanced head and neck cancer. Cetuximab in Chinese human head and neck cancer in the effectiveness and safety of the need to accumulate more information.